RFK hobbled the panel needed for smooth Lyme vaccine rollout

Key Points:

• A Lyme disease vaccine developed by Pfizer and Valneva has completed human trials and is preparing for FDA submission, but its availability is uncertain due to the disbandment and legal challenges facing the CDC’s Advisory Committee on Immunization Practices (ACIP), which typically recommends vaccine use and insurance coverage.
• In 2025, HHS Secretary Robert F. Kennedy Jr. dismissed the entire ACIP and appointed new members who faced a lawsuit for lacking proper credentials; a judge subsequently barred the committee from meeting or issuing vaccine recommendations, creating a major obstacle for the Lyme vaccine’s rollout.
• Lyme disease cases are rising sharply in Maine, with over 4,000 cases reported in 2025, driven by expanding tick populations and longer tick seasons; physicians and public health experts emphasize the urgent need for a vaccine amid challenges in diagnosis and treatment.
• Without ACIP guidance, vaccine recommendations and insurance coverage may become fragmented, relying on independent medical organizations and state policies, which could lead to confusion, limited vaccine uptake, and gaps in public health infrastructure.
• The new Pfizer-Valneva vaccine faces additional hurdles due to the legacy of a previous Lyme vaccine (LYMErix) that was withdrawn from the market, and concerns exist that the current administration’s vaccine skepticism may further undermine public trust and vaccine adoption.